Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound

Bykov, Vladimir J.N., Issaeva, Natalia, Shilov, Alexandre, Hultcrantz, Monica, Pugacheva, Elena, Chumakov, Peter, Bergman, Jan, Wiman, Klas G. +1 more·2002·Nature Medicine
DOI 10.1038/nm0302-282

Cited by (1,000)

Items 301–400 of 1,000

  1. Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53
    Michelle Martinez-Rivera, Zahid Hussain Siddik · 2011 · Biochemical Pharmacology
  2. Mitochondrially Targeted p53 Has Tumor Suppressor Activities In vivo
    Flaminia Talos, Oleksi Petrenko, Patricio Mena, Ute Martha Moll · 2005 · Cancer Research
  3. Primary Cultured Neurons Devoid of Cellular Prion Display Lower Responsiveness to Staurosporine through the Control of p53 at Both Transcriptional and Post-transcriptional Levels
    Erwan Paitel, Claire Sunyach, Cristine Alvès da Costa, Jean‐Christophe Bourdon, Bruno Vincent, Frédéric Checler · 2003 · Journal of Biological Chemistry
  4. Targeting Mutant p53 in Human Tumors
    Brian David Lehmann, Jennifer A. Pietenpol · 2012 · Journal of Clinical Oncology
  5. Low-Dose Valproic Acid Enhances Radiosensitivity of Prostate Cancer through Acetylated p53-Dependent Modulation of Mitochondrial Membrane Potential and Apoptosis
    Xufeng Chen, Jeffrey Y.C. Wong, Patty W. Wong, Eric H. Radany · 2011 · Molecular Cancer Research
  6. Beyond the Signal Sequence: Protein Routing in Health and Disease
    Cecilia Castro-Fernández, Guadalupe Maya‐Núñez, P. Michael Conn · 2004 · Endocrine Reviews
  7. Restoration of the Tumor Suppressor Function of Y220C-Mutant p53 by Rezatapopt, a Small-Molecule Reactivator
    Anna M. Puzio‐Kuter, Lizhong Xu, Mary Kate McBrayer, Romyr Dominique, Hongju H. Li, Bruce J. Fahr, Alyssa M. Brown, Amy E. Wiebesiek, Brandon M. Russo, Chris L. Mulligan et al. · 2025 · Cancer Discovery
  8. Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding
    Joel L. Kaar, Nicolas Basse, Andreas C. Joerger, Elaine Stephens, Trevor J. Rutherford, Alan Roy Fersht · 2010 · Protein Science
  9. MKL1 defines the H3K4Me3 landscape for NF-κB dependent inflammatory response
    Liming Yu, Fei Fang, Xin Jun Dai, Huihui Xu, Xiaohong Qi, Mingming Fang, Yong Xu · 2017 · Scientific Reports
  10. Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007
    Naoise C. Synnott, Matthias R. Bauer, Stephen F. Madden, Alyson M. Murray, Rut W. Klinger, Norma O’Donovan, Darran P. O’Connor, William M. Gallagher, John Paul Crown, Alan Roy Fersht et al. · 2017 · Cancer Letters
  11. Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer
    Shengliang Zhang, Lindsey Carlsen, Liz J. Hernández Borrero, Attila A. Seyhan, Xiaobing Tian, Wafik S. El‐Deiry · 2022 · Biomolecules
  12. APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells
    Dina Ali, Kerstin Jönsson‐Videsäter, Stefan Deneberg, Sofia Bengtzén, Hareth Nahi, Christer Paul, Sören Lehmann · 2010 · European Journal Of Haematology
  13. Apoptosis and Tumor Cell Death in Response to HAMLET (Human α-Lactalbumin Made Lethal to Tumor Cells)
    Oskar Hällgren, Sonja Aits, Patrick Brest, Lotta Gustafsson, Ann‐Kristin Mossberg, Björn Wullt, Catharina Svanborg · 2007 · Springer eBooks
  14. Oncogenic Intra-p53 Family Member Interactions in Human Cancers
    Maria A. Ferraiuolo, Silvia Di Agostino, Giovanni Blandino, Sabrina Strano · 2016 · Frontiers in Oncology
  15. PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines
    Patrícia Izetti, Agnès H. Hautefeuille, Ana Lúcia Abujamra, Caroline Brunetto de Farias, Juliana Giacomazzi, Bárbara Alemar, Guido Lenz, Rafael Roesler, Gilberto Schwartsmann, Alessandro Bersch Osvaldt et al. · 2014 · Investigational New Drugs
  16. PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein
    Hyder · 2009 · International Journal of Oncology
  17. PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53.
    2008 · PubMed Central
  18. Targeting p53 as a therapeutic strategy in sensitizing TRAIL-induced apoptosis in cancer cells
    Jing Zhao, Yixin Lü, Han‐Ming Shen · 2011 · Cancer Letters
  19. ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53
    Sullivan, Kelly D, Padilla-Just, Nuria, Henry, Ryan E, Porter, Christopher C, Kim, Jihye, Tentler, John J, Eckhardt, S Gail, Tan, Aik Choon, DeGregori, James, Espinosa, Joaquín M · 2012 · Nature Chemical Biology
  20. Def defines a conserved nucleolar pathway that leads p53 to proteasome-independent degradation
    Ting Tao, Hui Shi, Yihong Guan, Delai Huang, Ye Chen, David Philip Lane, Jun Chen, Jinrong Peng · 2013 · Cell Research
  21. Dangerous habits of a security guard: the two faces of p53 as a drug target
    Andrei V. Gudkov, Elena A. Komarova · 2007 · Human Molecular Genetics
  22. Design and synthesis of a C7-aryl piperlongumine derivative with potent antimicrotubule and mutant p53-reactivating properties
    Surendra Reddy Punganuru, Hanumantha Rao Madala, Sanjay N. Venugopal, Ramakrishna Samala, Constantinos Marios Mikelis, Kalkunte S. Srivenugopal · 2015 · European Journal of Medicinal Chemistry
  23. Stimulation of Suicidal Erythrocyte Death by PRIMA-1
    Caterina Faggio, Kousi Alzoubi, Salvatrice Calabrò, Florian J.W. Lang · 2015 · Cellular Physiology and Biochemistry
  24. Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma
    Hui Chen, Kristin F. Gotimer, Cristabelle De Souza, Clifford G. Tepper, Anthony Nicholas Karnezis, Gary Scott Leiserowitz, JEREMY R. CHIEN, Lloyd H. Smith · 2020 · Gynecologic Oncology
  25. Drug discovery and mutant p53
    Magdalena M. Maslon, Ted R. Hupp · 2010 · Trends in Cell Biology
  26. Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation
    Ingeborg Tinhofer, Volker Budach, Mohammad Reza Saki, Robert Konschak, Franziska Niehr, Korinna Jöhrens, Wilko Weichert, Annett Linge, Fabian Lohaus, Mechthild Krause et al. · 2016 · European Journal of Cancer
  27. Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors
    Tomi K. Sawyer · 2004 · Expert Opinion on Investigational Drugs
  28. Cytotoxic drug-induced, p53-mediated upregulation of caspase-8 in tumor cells
    Harald Ehrhardt, Sabine Häcker, S Wittmann, Martina Maurer, Arndt Borkhardt, Aleksandra D. Toloczko, Klaus‐Michael Debatin, Simone Fulda, Irmela Jeremias · 2007 · Oncogene
  29. CP-31398 Restores DNA-binding Activity to Mutant p53 in Vitro but Does Not Affect p53 Homologs p63 and p73
    Mark J. Demma, Serena Wong, Eugene Maxwell, Bimalendu Dasmahapatra · 2004 · Journal of Biological Chemistry
  30. Jasmonates induce nonapoptotic death in high‐resistance mutant p53‐expressing B‐lymphoma cells
    Orit Fingrut, Dorit Reischer, Ronit Rotem, Natalia Goldin, Irit Altboum, Israel Zan‐Bar, Eliezer Flescher · 2005 · British Journal of Pharmacology
  31. Wild type p53 reactivation: From lab bench to clinic
    Galina Selivanova · 2014 · FEBS Letters
  32. Emerging Non-Canonical Functions and Regulation by p53: p53 and Stemness
    David J. Olivos, Lindsey D. Mayo · 2016 · International Journal of Molecular Sciences
  33. Targeting the p53 signaling pathway in cancers: Molecular mechanisms and clinical studies
    Jinze Shen, Qurui Wang, Yunan Mao, Wei Gao, Shiwei Duan · 2023 · MedComm
  34. HAMLET triggers apoptosis but tumor cell death is independent of caspases, Bcl-2 and p53
    Oskar Hällgren, Lotta Gustafsson, Heikki Irjala, Galina Selivanova, Sten Orrenius, Catharina Svanborg · 2006 · APOPTOSIS
  35. Small molecule compounds targeting the p53 pathway: are we finally making progress?
    Xin Yu, Sumana Narayanan, Alexei Vázquez, Darren R. Carpizo · 2014 · APOPTOSIS
  36. Structural and Drug Targeting Insights on Mutant p53
    Ana Sara Gomes, Helena Ramos, Alberto Inga, Emı́lia Sousa, Lucı́lia Saraiva · 2021 · Cancers
  37. Dual Targeting of Wild-Type and Mutant p53 by Small Molecule RITA Results in the Inhibition of N-Myc and Key Survival Oncogenes and Kills Neuroblastoma Cells In Vivo and In Vitro
    Mikhail Burmakin, Yao Shi, Elisabeth Hedström, Per Kogner, Galina Selivanova · 2013 · Clinical Cancer Research
  38. Piperlongumine and p53-reactivator APR-246 selectively induce cell death in HNSCC by targeting GSTP1
    Wei Hang, Zhi-Xian Yin, Gang Liu, Qinghua Zeng, Xiangfeng Shen, Qianhui Sun, Dong‐Dong Li, Yong‐Ping Jian, Yang-He Zhang, Yishu Wang et al. · 2018 · Oncogene
  39. Chemotherapy response and resistance
    Soyoung Lee, Clemens A. Schmitt · 2003 · Current Opinion in Genetics & Development
  40. TP53 in Biology and Treatment of Osteosarcoma
    Kamil J. Synoradzki, Ewa Bartnik, Anna Malgorzata Czarnecka, Michał Fiedorowicz, Wiktoria Firlej, Anna Brodziak, Agnieszka Stasinska, Piotr Lukasz Rutkowski, Paweł Grieb · 2021 · Cancers
  41. PRIMA‐1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion
    Hareth Nahi, Mats Merup, Sören Lehmann, Sofia Bengtzén, Lars Möllgård, Galina Selivanova, Klas G. Wiman, Christer Paul · 2005 · British Journal of Haematology
  42. TGF-β induces TIAF1 self-aggregation via type II receptor-independent signaling that leads to generation of amyloid β plaques in Alzheimer's disease
    M-H Lee, S-R Lin, J-Y Chang, Lori Schultz, J Heath, L-J Hsu, Y-M Kuo, Qunying Hong, M-F Chiang, C-X Gong et al. · 2010 · Cell Death and Disease
  43. Simulations of mutant p53 DNA binding domains reveal a novel druggable pocket
    Mohan R. Pradhan, Jia Wei Siau, Srinivasaraghavan Kannan, Minh N. Nguyen, Zohra Ouaray, Chee Keong Kwoh, David Philip Lane, Farid John Ghadessy, Chandra Shekhar Verma · 2019 · Nucleic Acids Research
  44. p53 in the CNS: Perspectives on Development, Stem Cells, and Cancer
    Susan M. Mendrysa, Sara Ghassemifar, Reem A. Malek · 2011 · Genes & Cancer
  45. A Balancing Act: p53 Activity from Tumor Suppression to Pathology and Therapeutic Implications
    Mengxiong Wang, Laura Donatella Attardi · 2021 · Annual Review of Pathology Mechanisms of Disease
  46. APR-246 triggers ferritinophagy and ferroptosis of diffuse large B-cell lymphoma cells with distinct TP53 mutations
    Yuheng Hong, Tianyuan Ren, Xiaoxuan Wang, Xia Liu, Yue Fei, Shen Meng, Xu Han, Cong Sun, Hongru Shen, Lanfang Li et al. · 2022 · Leukemia
  47. Targeting mutant p53: a key player in breast cancer pathogenesis and beyond
    Hina Qayoom, Burhan Ul Haq, Shazia Sofi, Nusrat Jan, Asma Jan, Manzoor Ahmad Mir · 2024 · Cell Communication and Signaling
  48. The α,α-Difluorinated Phosphonate L-pSer-Analogue: An Accessible Chemical Tool for Studying Kinase- Dependent Signal Transduction
    Kaushik Panigrahi, MariJean Eggen, Jun-Ho Maeng, Quanrong Shen, David B. Berkowitz · 2009 · Chemistry & Biology
  49. PRIMA-1MET/APR-246 targets mutant forms of p53 family members p63 and p73
    Nina Rökaeus, Jinfeng Shen, Ines Eckhardt, Vladimir J.N. Bykov, Klas G. Wiman, Margareta Wilhelm · 2010 · Oncogene
  50. Autophagy induced by p53-reactivating molecules protects pancreatic cancer cells from apoptosis
    Claudia Fiorini, Marta Menegazzi, Chiara Padroni, Ilaria Dando, Elisa Dalla Pozza, Alex Gregorelli, Chiara Costanzo, Marta Palmieri, Massimo Donadelli · 2012 · APOPTOSIS
  51. Effects of PRIMA‐1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion
    Hareth Nahi, Sören Lehmann, Lars Möllgård, Sofia Bengtzén, Galina Selivanova, Klas G. Wiman, Christer Paul, Mats Merup · 2004 · British Journal of Haematology
  52. Restoring p53 Function in Head and Neck Squamous Cell Carcinoma to Improve Treatments
    Tycho de Bakker, Fabrice Journé, Géraldine Descamps, Sven Saussez, Tatiana Dragan, Ghanem Ghanem, Mohammad Krayem, Dirk Van Gestel · 2022 · Frontiers in Oncology
  53. Reactivation of p53 mutants by p53 reactivation and induction of massive apoptosis in thyroid cancer cells
    Rosa Linda Messina, Mariangela Sanfilippo, Veronica Vella, Giuseppe Pandini, Paolo Giovanni Vigneri, Maria Luisa Nicolosi, Fiorenza Gianì, Riccardo Vigneri, Francesco Frasca · 2011 · International Journal of Cancer
  54. Redox modulation of p53: Mechanisms and functional significance
    Do‐Hee Kim, Joydeb Kumar Kundu, Young‐Joon Surh · 2011 · Molecular Carcinogenesis
  55. Analysis of cell cycle-related proteins in mediastinal lymph nodes of patients with N2-NSCLC obtained by EBUS-TBNA: relevance to chemotherapy response
    Sherif A.A. Mohamed, Kazuhiro Yasufuku, Takahiro Nakajima, Kenzo Hiroshima, R Kubo, Akira Iyoda, Shigetoshi Yoshida, M Suzuki, Yasuo Sekine, Kiyoshi Shibuya et al. · 2008 · Thorax
  56. Nicotine-induced survival signaling in lung cancer cells is dependent on their p53 status while its down-regulation by curcumin is independent
    Vineshkumar Thidil Puliyappadamba, Vino T. Cheriyan, Arun Kumar T. Thulasidasan, Smitha Vadakkeveettil Bava, Vinod Balachandran, Priya Ramesh Prabhu, Ranji Varghese, Arathy Bevin, Shalini Venugopal, Ruby John Anto · 2010 · Molecular Cancer
  57. p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib
    Mohammad Krayem, Fabrice Journé, Murielle Wiedig, Renato Morandini, Ahmad Najem, François Salès, Léon C.L.T. van Kempen, Catherine Sibille, Ahmad Hussein Awada, Jean‐Christophe Marine et al. · 2016 · European Journal of Cancer
  58. P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition
    Ahmad Najem, Mohammad Krayem, François Salès, Nader Hussein, Bassam M. Badran, Caroline Robert, Ahmad Hussein Awada, Fabrice Journé, Ghanem Ghanem · 2017 · European Journal of Cancer
  59. Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells
    Abdur Rehman, Manpreet S. Chahal, Xiaoting Tang, James E. Bruce, Yves G. Pommier, Sayed S. Daoud · 2005 · Breast Cancer Research
  60. Restoring the p53 ‘Guardian’ Phenotype in p53-Deficient Tumor Cells with CRISPR/Cas9
    Chira, Sergiu, Gulei, Diana, Hajitou, Amin, Berindan-Neagoe, Ioana · 2018 · Trends in Biotechnology
  61. When the guardian sleeps: Reactivation of the p53 pathway in cancer
    Olaf Merkel, Ninon Taylor, Nicole Prutsch, Philipp Bernhard Staber, Richard Moriggl, Suzanne Dawn Turner, Lukas Kenner · 2017 · Mutation Research/Reviews in Mutation Research
  62. The Role of microRNAs in the Regulation of Apoptosis in Lung Cancer and Its Application in Cancer Treatment
    Norahayu Othman, Noor Hasima Nagoor · 2014 · BioMed Research International
  63. Identification and Functional Characterization of the Human Glutathione S-Transferase P1 Gene as a Novel Transcriptional Target of the p53 Tumor Suppressor Gene
    Hui‐Wen Lo, Lisa Stephenson, Xinyu Cao, Mira Milas, Raphael E. Pollock, Francis Ali‐Osman · 2008 · Molecular Cancer Research
  64. Phytochemicals Approach for Developing Cancer Immunotherapeutics
    Shu-Yi Yin, Ning-Sun Yang, Tien-Jen Lin · 2017 · Frontiers in Pharmacology
  65. Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway
    Li, Yin, Mao, Yuehua, Brandt-Rauf, Paul W., Williams, Ann C., Fine, Robert L. · 2005 · Molecular Cancer Therapeutics
  66. Structural and Functional Basis for Therapeutic Modulation of p53 Signaling
    Emily A. Bassett, Wenge Wang, Farzan Rastinejad, Wafik S. El‐Deiry · 2008 · Clinical Cancer Research
  67. Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties
    Huaxin Song, Jiale Wu, Yigang Tang, Yuting Dai, Xinrong Xiang, Ya Li, Lili Wu, Jiaqi Wu, Ying Liang, Yangfei Xing et al. · 2023 · Science Translational Medicine
  68. Radiation and SN38 treatments modulate the expression of microRNAs, cytokines and chemokines in colon cancer cells in a p53-directed manner
    Surajit Pathak, Wenjian Meng, Suman Kumar Nandy, Jie Ping, Atıl Bişgin, Linda Helmfors, Patrik Waldmann, Xiao-Feng Sun · 2015 · Oncotarget
  69. Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets
    Yi Miao, Leonard Jeffrey Medeiros, Zijun Yidan Xu-Monette, Jianyong Li, Ken H. Young · 2019 · Frontiers in Oncology
  70. Targeting centrosome amplification, an Achilles' heel of cancer
    Dorota Sabat‐Pośpiech, Kim Fabian‐Kolpanowicz, Ian A. Prior, Judy M. Coulson, Andrew B. Fielding · 2019 · Biochemical Society Transactions
  71. Functional Classification of TP53 Mutations in Acute Myeloid Leukemia
    Sayantanee Dutta, Gudrun Pregartner, Frank G. Rücker, Ellen Heitzer, Armin Zebisch, Lars Bullinger, Andrea Berghold, Konstanze Döhner, Heinz Sill · 2020 · Cancers
  72. Activation of Mutant Enzyme Function In Vivo by Proteasome Inhibitors and Treatments that Induce Hsp70
    Laishram Rajendrakumar Singh, Sapna Gupta, Nicholaas H. Honig, Jan Peter Kraus, Warren D. Kruger · 2010 · PLoS Genetics
  73. Structural and sequential context of p53: A review of experimental and theoretical evidence
    Taniya Saha, Rajiv K. Kar, Gaurisankar Sa · 2014 · Progress in Biophysics and Molecular Biology
  74. Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia
    Salih Demir, Elena Boldrin, Qian Sun, Stephanie Hampp, Eugen Tausch, Cornelia Eckert, Martin Ebinger, Rupert Handgretinger, Geertruy te Kronnie, Lisa Wiesmüller et al. · 2019 · Haematologica
  75. p53 in the Cytoplasm
    Nicole Baptiste, Carol L. Prives · 2004 · Cell
  76. Erratum: PRIMA-1Met induces mitochondrial apoptosis through activation of caspase-2
    Jinfeng Shen, Helin Vakifahmetoglu, Hélène Stridh, Boris Zhivotovsky, Klas G. Wiman · 2016 · Oncogene · Retracted
  77. A novel PTEN/mutant p53/c-Myc/Bcl-XL axis mediates context-dependent oncogenic effects of PTEN with implications for cancer prognosis and therapy
    Huang, Xiaoping, Zhang, Ying, Tang, Yaqiong, Butler, Napoleon, Kim, Jungeun, Guessous, Fadila, Schiff, David, Mandell, James, Abounader, Roger · 2013 · Neoplasia
  78. Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse
    Fan Yang, Samuel W. Brady, Chao Shu Tang, Huiying Sun, Lijuan Du, Malwine Barz, Xiaotu Ma, Yao Chen, Houshun Fang, Xiaomeng Li et al. · 2021 · Nature Cancer
  79. p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma
    Phaik Ju Teoh, Wee Joo Chng · 2014 · BioMed Research International
  80. Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?
    Paola Menichini, Paola Monti, Andrea Speciale, Giovanna Cutrona, Serena Matis, Franco Fais, Elisa Taìana, Antonino Neri, Riccardo Bomben, Massimo Gentile et al. · 2021 · Cells
  81. Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells
    Basant Kumar Thakur, Tino Dittrich, Prakash Chandra, Annette Becker, Wolfgang Kuehnau, Jan‐Henning Klusmann, Dirk Reinhardt, Karl Welte · 2012 · International Journal of Cancer
  82. Small Molecules That Target Protein Misfolding
    Lori Krim Gavrin, R. Aldrin Denny, Eddine Saiah · 2012 · Journal of Medicinal Chemistry
  83. Targeting PML in triple negative breast cancer elicits growth suppression and senescence
    Leire Arreal, Marco Piva, Sonia Fernández, Ajinkya Revandkar, Ariane Schaub-Clerigué, Josep Villanueva, Amaia Zabala‐Letona, Mikel Pujana-Vaquerizo, Ianire Astobiza, Ana R. Cortázar et al. · 2019 · Cell Death and Differentiation
  84. Rescue of embryonic stem cells from cellular transformation by proteomic stabilization of mutant p53 and conversion into WT conformation
    Noa Rivlin, Shir Katz, Maayan Doody, Michal Sheffer, Stav Horesh, Alina Molchadsky, Gabriela Koifman, Yoav Shetzer, Naomi Goldfinger, Varda Rotter et al. · 2014 · Proceedings of the National Academy of Sciences
  85. Roles of TP53 in determining therapeutic sensitivity, growth, cellular senescence, invasion and metastasis
    James Andrew McCubrey, Kvin Lertpiriyapong, Timothy Louis Fitzgerald, Alberto Maria Martelli, Lucio Cocco, Dariusz Rakus, Agnieszka Gizak, Massimo Libra, Melchiorre Cervello, Guiseppe Montalto et al. · 2016 · Advances in Biological Regulation
  86. PRIMA-1MET induces mitochondrial apoptosis through activation of caspase-2
    Jinfeng Shen, Helin Vakifahmetoglu, Hélène Stridh, Boris Zhivotovsky, Klas G. Wiman · 2008 · Oncogene · Retracted
  87. Genomic Alterations in Head and Neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT)
    Grégoire Marret, Ivan Bièche, Célia Dupain, Édith Borcoman, Pauline du Rusquec, Francesco Ricci, S. Hescot, Marie‐Paule Sablin, Patricia Tresca, Diana Bello et al. · 2021 · JCO Precision Oncology
  88. RUNX Family Participates in the Regulation of p53-Dependent DNA Damage Response
    Toshinori Ozaki, Akira Nakagawara, Hiroki Nagase · 2013 · International Journal of Genomics
  89. Pharmacological activation of the p53 pathway in haematological malignancies
    Manujendra N. Saha, Johann Micallef, Lugui Qiu, Hong Chang · 2009 · Journal of Clinical Pathology
  90. Novel cancer therapy by reactivation of the p53 apoptosis pathway
    Vladimir J.N. Bykov, Klas G. Wiman · 2003 · Annals of Medicine
  91. Toward a More Precise Future for Oncology
    Murciano-Goroff, Yonina R., Taylor, Barry S., Hyman, David M., Schram, Alison M. · 2020 · Cancer Cell
  92. Curaxin CBL0137 Exerts Anticancer Activity via Diverse Mechanisms
    Mingzhu Jin, Bai-Rong Xia, Yu Xu, Weilin Jin · 2018 · Frontiers in Oncology
  93. The changing face of p53 in head and neck cancer
    Maxine Partridge, Daniela Elena Costea, X. Huang · 2007 · International Journal of Oral and Maxillofacial Surgery
  94. High-throughput amplicon scanning of the TP53 gene in breast cancer using high-resolution fluorescent melting curve analyses and automatic mutation calling
    Roy R. L. Bastien, Tracey B. Lewis, Jason Ezra Hawkes, John F. Quackenbush, Thomas C. Robbins, Juan Palazzo, Charles M. Perou, Philip Seth Bernard · 2008 · Human Mutation
  95. Mutant p53 proteins: Between loss and gain of function
    Sabrina Strano, Stefania Dell’Orso, Adriana Maria Mongiovi, Olimpia Monti, Eleonora Lapi, Silvia Di Agostino, Giulia Fontemaggi, Giovanni Blandino · 2006 · Head & Neck
  96. Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell Formation
    Yoav Shetzer, Alina Molchadsky, Varda Rotter · 2016 · Cold Spring Harbor Perspectives in Medicine
  97. Anti‐leukaemic effects induced by APR‐246 are dependent on induction of oxidative stress and the NFE2L2/HMOX1 axis that can be targeted by PI3K and mTOR inhibitors in acute myeloid leukaemia cells
    Ali, Dina, Mohammad, Dara K., Mujahed, Huthayfa, Jonson‐Videsäter, Kerstin, Nore, Beston, Paul, Christer, Lehmann, Sören · 2016 · British Journal of Haematology
  98. Off-Target Lapatinib Activity Sensitizes Colon Cancer Cells Through TRAIL Death Receptor Up-Regulation
    Nathan G. Dolloff, Patrick A. Mayes, Lori S. Hart, David T. Dicker, Robin C. Humphreys, Wafik S. El‐Deiry · 2011 · Science Translational Medicine
  99. Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas
    Annette Künkele, Katleen De Preter, Lukas Carl Heukamp, T. Thor, Kristian W. Pajtler, Wolfgang Hartmann, Michel Guy André Mittelbronn, Michael Andreas Grotzer, Hedwig E. Deubzer, Frank Speleman et al. · 2012 · Neuro-Oncology
  100. PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms
    Xiaolan Li, Jianbiao Zhou, Zit-Liang Chan, Jing-Yuan Chooi, Zhirong Chen, Wee Joo Chng · 2015 · Oncotarget